Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.52 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.52 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.52 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 10/20 | 0.40 |
| ▸ | EP300 | Q09472 | 9/20 | 0.40 |
| ▸ | BRD4 | O60885 | 3/20 | 0.40 |
| ▸ | SPR | P35270 | 1/20 | 0.36 |
| ▸ | CFTR | P13569 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1006514 | 0.89 | DPP4 (0.50) | DPP4DPP8DPP7DPP9MAPK1 | |
| SCHEMBL17868650 | 0.82 | CREBBP (0.43) | DPP4DPP8DPP7DPP9MAPK1 | |
| SCHEMBL20818349 | 0.78 | CREBBP (0.44) | MAPK1CREBBPEP300BRD4 | |
| SCHEMBL5644483 | 0.77 | DPP4 (0.50) | DPP4DPP8DPP7DPP9 | |
| SCHEMBL14970423 | 0.76 | MAPK1 (0.56) | DPP4DPP8DPP7DPP9MAPK1 | |
| SCHEMBL23881432 | 0.75 | DPP4 (0.40) | DPP4DPP8DPP7DPP9SPR | |
| SCHEMBL5953472 | 0.75 | HCAR2 (0.56) | MAPK1CREBBPEP300BRD4 | |
| SCHEMBL17785675 | 0.75 | CREBBP (0.47) | MAPK1CREBBPEP300BRD4 | |
| SCHEMBL4761723 | 0.75 | CREBBP (0.47) | MAPK1CREBBPEP300BRD4 | |
| SCHEMBL17785865 | 0.75 | CREBBP (0.44) | MAPK1CREBBPEP300BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7265128-B2 | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK & CO., INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-20060069116-A1 | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME LLC | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069116-A1 | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | DPP4, DPP3, DPP7 | DPP4 1/4885DPP8 5/4885DPP7 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.